Shaw Gary X, Li Yue, Shi Genbin, Wu Yan, Cherry Scott, Needle Danielle, Zhang Di, Tropea Joseph E, Waugh David S, Yan Honggao, Ji Xinhua
Macromolecular Crystallography Laboratory, National Cancer Institute, Frederick, MD, USA.
FEBS J. 2014 Sep;281(18):4123-37. doi: 10.1111/febs.12896. Epub 2014 Jul 23.
Two valid targets for antibiotic development, 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase (HPPK) and dihydropteroate synthase (DHPS), catalyze consecutive reactions in folate biosynthesis. In Francisella tularensis (Ft), these two activities are contained in a single protein, FtHPPK-DHPS. Although Pemble et al. (PLoS One 5, e14165) determined the structure of FtHPPK-DHPS, they were unable to measure the kinetic parameters of the enzyme. In this study, we elucidated the binding and inhibitory activities of two HPPK inhibitors (HP-18 and HP-26) against FtHPPK-DHPS, determined the structure of FtHPPK-DHPS in complex with HP-26, and measured the kinetic parameters for the dual enzymatic activities of FtHPPK-DHPS. The biochemical analyses showed that HP-18 and HP-26 have significant isozyme selectivity, and that FtHPPK-DHPS is unique in that the catalytic efficiency of its DHPS activity is only 1/260,000 of that of Escherichia coli DHPS. Sequence and structural analyses suggest that HP-26 is an excellent lead for developing therapeutic agents for tularemia, and that the very low DHPS activity is due, at least in part, to the lack of a key residue that interacts with the substrate p-aminobenzoic acid (pABA). A BLAST search of the genomes of ten F. tularensis strains indicated that the bacterium contains a single FtHPPK-DHPS. The marginal DHPS activity and the single copy existence of FtHPPK-DHPS in F. tularensis make this bacterium more vulnerable to DHPS inhibitors. Current sulfa drugs are ineffective against tularemia; new inhibitors targeting the unique pABA-binding pocket may be effective and less subject to resistance because any mutations introducing resistance may make the marginal DHPS activity unable to support the growth of F. tularensis.
The coordinates and structure factors have been deposited in the Protein Data Bank under accession code 4PZV.
抗生素研发的两个有效靶点,6-羟甲基-7,8-二氢蝶呤焦磷酸激酶(HPPK)和二氢蝶酸合酶(DHPS),催化叶酸生物合成中的连续反应。在土拉弗朗西斯菌(Ft)中,这两种活性包含在单一蛋白质FtHPPK-DHPS中。尽管Pemble等人(《公共科学图书馆·综合》5,e14165)确定了FtHPPK-DHPS的结构,但他们无法测量该酶的动力学参数。在本研究中,我们阐明了两种HPPK抑制剂(HP-18和HP-26)对FtHPPK-DHPS的结合和抑制活性,确定了FtHPPK-DHPS与HP-26复合物的结构,并测量了FtHPPK-DHPS双重酶活性的动力学参数。生化分析表明,HP-18和HP-26具有显著的同工酶选择性,并且FtHPPK-DHPS的独特之处在于其DHPS活性的催化效率仅为大肠杆菌DHPS的1/260,000。序列和结构分析表明,HP-26是开发兔热病治疗药物的优秀先导化合物,并且极低的DHPS活性至少部分归因于缺乏与底物对氨基苯甲酸(pABA)相互作用的关键残基。对十种土拉弗朗西斯菌菌株基因组的BLAST搜索表明,该细菌含有单一的FtHPPK-DHPS。FtHPPK-DHPS在土拉弗朗西斯菌中的边缘DHPS活性和单拷贝存在使该细菌更容易受到DHPS抑制剂的影响。目前的磺胺类药物对兔热病无效;针对独特的pABA结合口袋的新抑制剂可能有效且不易产生耐药性,因为任何引入耐药性的突变可能会使边缘的DHPS活性无法支持土拉弗朗西斯菌的生长。
坐标和结构因子已存入蛋白质数据库,登录号为4PZV。